Edwards Lifesciences Logo
US28176E1082
936853
EW

Edwards Lifesciences

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 98,66 € (+1,98 %). La mediana es de 99,84 € (+3,20 %).

Comprar
  34
Mantener
  15
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • CMS guideline on TAVR reimbursement strengthens Edwards Lifesciences

    US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » Más en de.investing.com


  • Edwards Lifesciences noted as leader in TAVR growth by Aristotle Value fund

    Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » Más en finance.yahoo.com


  • Edwards Lifesciences reaches new 52-week high at 92.94 USD

    Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Más en de.investing.com


  • Edwards Lifesciences hits 52-week high of $87.89 after strong Q1

    Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » Más en de.investing.com


  • Edwards Lifesciences names Doretta Mistras chief financial officer

    Edwards Lifesciences has appointed Doretta Mistras as corporate vice president and CFO; she will assume the role at the end of May and succeeds Scott Ullem, who had already announced his departure and will remain as a strategic adviser during the transition. Mistras joins from Viatris, where she had served since March 2024 as CFO of the global finance organization and previously held leadership roles in healthcare investment banking at Citigroup and Goldman Sachs. The company has a market capitalization of $48 billion, revenue growth of 14% and a gross profit margin of nearly 78%; the stock is trading near its 52-week high. Analysts have recently cut their earnings forecasts (13 analysts), giving the CFO change added significance. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Edwards Lifesciences tuvo unos ingresos de 1514,53 M € y un beneficio neto de 271,48 M €
(EUR) septiembre de 2026
YoY
Ingresos 1514,53 M 14,44 %
Beneficio bruto 1188,58 M 15,31 %
Beneficio neto 271,48 M 9,44 %
EBITDA 360,29 M 9,08 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
55,21 mil M €
Número de acciones
575 M
Máximo/mínimo de 52 semanas
96,90 € - 67,76 €
Dividendos No
Beta
0,85
Ratio P/E
59,77
Ratio PEG
-2,49
Ratio P/B
5,61
Ratio P/S
9,11

Perfil de la empresa

Edwards Lifesciences Corporation proporciona productos y tecnologías para enfermedades estructurales del corazón, así como para cuidados críticos y monitorización quirúrgica en Estados Unidos, Europa, Japón e internacionalmente. Ofrece productos de reemplazo de válvulas cardíacas por vía transcatéter para el reemplazo mínimamente invasivo de válvulas cardíacas; y productos de reparación y reemplazo de válvulas cardíacas por vía transcatéter para tratar enfermedades de las válvulas mitral y tricúspide. La compañía también proporciona los sistemas de reparación de válvulas por vía transcatéter PASCAL y Cardioband para terapia mínimamente invasiva. Además, ofrece soluciones estructurales cardíacas quirúrgicas, como una válvula aórtica quirúrgica con el nombre INSPIRIS; KONECT RESILIA, un conducto valvulado de tejido aórtico preensamblado para pacientes que requieren el reemplazo de la válvula, la raíz y la aorta ascendente; y el sistema de reparación de válvula mitral HARPOON Beating Heart para pacientes con insuficiencia mitral degenerativa. Asimismo, la compañía proporciona soluciones de cuidados críticos, incluidos sistemas avanzados de monitorización hemodinámica para medir la función cardíaca y el estado de fluidos de un paciente en entornos quirúrgicos y de cuidados intensivos; y el software Acumen Hypotension Prediction Index, que alerta a los clínicos con antelación cuando un paciente desarrolla una presión arterial peligrosamente baja. La compañía distribuye sus productos a través de una fuerza de ventas directa y distribuidores independientes. Edwards Lifesciences Corporation fue fundada en 1958 y tiene su sede en Irvine, California.

Nombre
Edwards Lifesciences
CEO
Bernard J. Zovighian
Sede Irvine, ca
Estados Unidos
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
27/03/2000
Empleados 16.000

Símbolos bursátiles

Bolsa Símbolo
NYSE
EW
XETRA
EWL.DE
Frankfurt
EWL.F
Düsseldorf
EWL.DU
Milan
1EW.MI
London
0REN.L
SIX
EW.SW
München
EWL.MU
Wien
EWLS.VI
🍪

Parqet  usa cookies. Más información